Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies

Arthritis and Rheumatism

Volumn 64, Issue 9, 2012, Pages 3043-3051

  Molloy, Eamonn S ^a   Calabrese, Leonard H ^b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CHLORAMBUCIL; CIDOFOVIR; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; MEFLOQUINE; METHOTREXATE; MIRTAZAPINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ADVERSE OUTCOME; AGED; ANTIVIRAL THERAPY; ARTICLE; CHEMOTHERAPY; DATA BASE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; WEGENER GRANULOMATOSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; RHEUMATIC DISEASES;

EID: 84865315420     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34468     Document Type: Article

References (20)

1. Calabrese LH, Molloy ES, Huang D, Ransohoff RM,. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease [review]. Arthritis Rheum 2007; 56: 2116-28.
2. Molloy ES, Calabrese LH,. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009; 60: 3761-5.
3. Harris HE,. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology (Oxford) 2008; 47: 224-5.
4. Fleischmann RM,. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009; 60: 3225-8.
5. Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68: 1156-64.
6. Kumar D, Bouldin TW, Berger RG,. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum 2010; 62: 3191-5.
7. Rituxan warning. FDA Consum 2007; 41: 3.
8. Calabrese LH, Molloy ES,. Therapy: rituximab and PML risk-informed decisions needed! Nat Rev Rheumatol 2009; 5: 528-9.
9. Carson KR, Bennett CL,. Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating. Leuk Lymphoma 2009; 50: 323-4.
10. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-40.
11. US Food and Drug Administration. Important drug warning regarding Rituxan (rituximab). October 2009. URL: http://www.fda.gov/downloads/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM187792.pdf.
12. Marie I, Guegan-Massardier E, Levesque H,. Progressive multifocal leukoencephalopathy in refractory polymyositis treated with rituximab. Eur J Intern Med 2011; 22: e13-4.
13. Tuccori M, Focosi D, Blandizzi C, Del Tacca M, Petrini M,. Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009; 101: 1288-9.
14. World Health Organization. Adverse Events Following Immunization (AEFI): causality assessment. URL: http://www.who.int/vaccines-documents/DocsPDF05/815. pdf.
15. European Medicines Agency. Keller Stanislawski B. Natalizumab (Tysabri) and PML-the current figures. July 2011. URL: http://www.ema.europa.eu/docs/en- GB/document-library/Presentation/2011/07/WC500109631.pdf.
16. Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M, Dal Pan G,. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011; 65: 546-51.
17. Grinyo J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010; 90: 1521-7.
18. US Food and Drug Administration. Novartis. Important drug warning: important change in the Myfortic (mycophenolic acid) complete prescribing information-postmarketing reports of progressive multifocal leukoencephalopathy (PML). June 2008. URL: http://www.fda.gov/downloads/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm126447.pdf.
19. US Food and Drug Administration. Roche. Important drug warning: important changes in the CellCept (mycophenolate mofetil) prescribing information-reports of progressive multifocal leukoencephalopathy (PML) in patients treated with CellCept. June 2008. URL: http://www.fda.gov/downloads/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM136360.pdf
20. Neff RT, Hurst FP, Falta EM, Bohen EM, Lentine KL, Dharnidharka VR, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008; 86: 1474-8.